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Abstract
Aim
The present study aimed to evaluate the effects of gene variants in key genes influencing
pharmacokinetic and pharmacodynamic of carbamazepine (CBZ) on the response in
patients with epilepsy.
Materials & Methods
Five SNPs in two candidate genes influencing CBZ transport and metabolism, namely
ABCB1 or EPHX1, and CBZ response SCN1A (sodium channel) were genotyped in 145
epileptic patients treated with CBZ as monotherapy and 100 age and sex matched healthy
controls. Plasma concentrations of CBZ, carbamazepine-10,11-epoxide (CBZE) and
carbamazepine-10,11-trans dihydrodiol (CBZD) were determined by HPLC-UV-DAD and
adjusted for CBZ dosage/kg of body weight.
Results
The presence of the SCN1A IVS5-91G>A variant allele is associated with increased epi-
lepsy susceptibility. Furthermore, carriers of the SCN1A IVS5-91G>A variant or of EPHX1
c.337T>C variant presented significantly lower levels of plasma CBZ compared to carriers
of the common alleles (0.71±0.28 vs 1.11±0.69 μg/mL per mg/Kg for SCN1A IVS5-91 AA vs
GG and 0.76±0.16 vs 0.94±0.49 μg/mL per mg/Kg for EPHX1 c.337 CC vs TT; P<0.05 for
both). Carriers of the EPHX1 c.416A>G showed a reduced microsomal epoxide hydrolase
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activity as reflected by a significantly decreased ratio of CBZD to CBZ (0.13±0.08 to 0.26
±0.17, p<0.05) also of CBZD to CBZE (1.74±1.06 to 3.08±2.90; P<0.05) and CDRCBZD
(0.13±0.08 vs 0.24±0.19 μg/mL per mg/Kg; P<0.05). ABCB1 3455C>T SNP and SCN1A
3148A>G variants were not associated with significant changes in CBZ pharmacokinetic.
Patients resistant to CBZ treatment showed increased dosage of CBZ (657±285 vs 489
±231 mg/day; P<0.001) but also increased plasma levels of CBZ (9.84±4.37 vs 7.41
±3.43 μg/mL; P<0.001) compared to patients responsive to CBZ treatment. CBZ resistance
was not related to any of the SNPs investigated.
Conclusions
The SCN1A IVS5-91G>A SNP is associated with susceptibility to epilepsy. SNPs in EPHX1
gene are influencing CBZ metabolism and disposition. CBZ plasma levels are not an indica-
tor of resistance to the therapy.
Introduction
Epilepsy is a disease that cannot be described by only a single condition, but it rather represents
a family of diverse disorders, having in common an abnormally increased predisposition to sei-
zures, which occur due to abnormal, excessive or synchronous brain neuronal activity [1].
Prevalence of epilepsy is higher in developing countries and also slightly higher in lower socio-
economic classes. It occurs in all strata in a population, and males are more predisposed com-
pared to females. About 40% of patients develop epilepsy below the age of 16 years and about
20% over the age of 65 years, with a frequency that different studies have shown to vary
between 50 and 120 per 100,000 individuals per year [2]. Carbamazepine (CBZ) belongs to one
of the most prescribed anticonvulsant drugs for treatment of generalized tonico-clonic and
complex partial epileptic seizures [3]. As several other antiepileptic drugs, CBZ is a substrate of
the human P-glycoprotein (Pgp) transporter [4]. CBZ is metabolized in the liver through an
oxidative, epoxidase pathway catalyzed by CYP3A4 and other CYP enzymes followed by epox-
ide hydrolase mediated pathway. This leads to the formation of CBZ-10,11-epoxide (CBZ-E),
the major CBZ metabolite, which possesses a potent anticonvulsant effect, before further
metabolism by microsomal epoxide hydrolase (mEH) and excretion as inactive CBZ-
10,11-diol (CBZ-diol) [5,6].
From the pharmacological point of view, CBZ exerts a combined antiepileptic action by
use-dependent blockage of neuronal sodium channels in a voltage and frequency dependent
manner by delaying their recovery from the inactivated state, through reduction of the number
of action potentials within a burst and decrease of burst duration [7,8].
Clinically, CBZ is characterized by important inter and/or intraindividual variation in drug
pharmacokinetics and by different patient susceptibility to adverse reactions. As a conse-
quence, the therapeutic efficacy of CBZ, as well as those of other similar antiepileptic drugs,
seems to correlate better with blood levels than with doses [9,10]. For these reasons, therapeutic
drug monitoring emerged as an essential tool for therapy optimization and for minimizing the
side effects arising due to excessive drug blood concentrations (or to avoid lack of pharmaco-
logical effect due to its lower than expected blood levels) [11].
In addition, and above all, as seizures can effectively be pharmacologically suppressed, a
high percentage of patients (30–40%) exhibit pharmacoresistance independently from
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medication non-compliance, significant provoking factors, inappropriate drug or doses, or
progressive neurological diseases [12,13]. The main proposed cause for CBZ pharmacoresis-
tance is the genetic polymorphism existing in genes encoding for proteins associated with CBZ
metabolizing enzymes (mediated by CYP3A4, CYP3A5, CYP2C9, CYP2C19 and EPHX1),
transporter proteins (ABCB1, ABCC1), or target proteins and receptors (SCN1A, SCN2A).
Understanding of these may enable prediction of drug resistance and optimization of therapeu-
tic strategies [14–18]. However, studies investigating the effect of SNPs of a variety of genes on
CBZ metabolism in different populations have achieved, in several cases, contradictory conclu-
sions, probably due to geographical/genetically differences existing among the studied popula-
tions [19–28].
The present study aimed to evaluate the potential associations between SNPs of key genes
encoding for the major drug transporter protein ABCB1, for the metabolizing enzyme EPHX1,
and for the sodium channel SCN1A, as genes involved in the metabolism and disposition of
CBZ, and CBZ plasma levels in epileptic patients treatment.
Materials and Methods
Subjects
All the procedures in this study were conducted according to guidelines in the Declaration of
Helsinki and the study design was approved by Ethics Committee in Faculty of Medicine, Uni-
versity of Prishtina—Hasan Prishtina and University Clinical Center of Kosovo (Prishtina,
Kosovo). All patients gave written informed consent. A total of 145 patients with epilepsy (82
males and 63 females) between the ages of 18–70 years were included in the study. Patients
were treated with CBZ monotherapy for at least 1 year at Neurology Clinic in the University
Clinical Center of Prishtina. All patients were not receiving pharmacological treatment for
other pathologies. Patients’ renal and hepatic functions were evaluated and those with abnor-
mal function were not included in the study. The classification of epilepsies and epileptic syn-
dromes were conducted according to the guidelines of the International League Against
Epilepsy [29]. A total of 100 unrelated healthy control individuals were also randomly recruited
from the same region and ethnicity to compare genotyping distribution. All patient were from
Kosovo and the following information was noted: gender, weight (kg), age, CBZ maintenance
dose (mg/kg per day), drug resistant patients (considered as occurrence of at least four seizures
over a period of 1 year during treatment with CBZ) and drug responsive patients (those sei-
zure-free for at least 1 year during treatment with CBZ) (Table 1). No dose adjustments were
allowed within 1 month prior to the collection of samples to ensure steady-state plasma con-
centrations of CBZ.
A total of 6 mL of fasting peripheral blood was drawn early in the morning from each
patient in EDTA and heparinized vacutainer blood collection tubes for DNA extraction and
analysis of plasma concentrations of CBZ and of its major metabolites.
The maintenance dose-adjusted concentrations of CBZ, CBZE and CBZD (CDRCBZ,
CDRCBZE, CDRCBZD) and the CBZE:CBZ, CBZD:CBZ and CBZD:CBZE ratios were used as
parameters for the evaluation of CBZ metabolism.
Genotyping
Genomic DNA was extracted from whole blood using a Purelink Genomic DNA extraction kit
according to the procedure recommended by the manufacturer (Invitrogen, CA, USA). The
genotypes of ABCB1 c.3435C>T (rs1045642), SCN1A c.3184A>G (rs2298771), IVS5–91
G>A (rs3812718), and EPHX1 c.416A>G (rs2234922), c.337T>C (rs1051740), polymor-
phisms were analyzed using SNP specific Taqman probes Vic and Fam reporter dyes,
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according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA). DNA
samples were diluted to a concentration of 10 ng/μL. The assays were run using a reaction vol-
ume of 15 μL, consisting of 7.5 μL of Applied Biosystems TaqMan Genotyping Master Mix,
0.75 μL of TaqMan SNP Genotyping Assays and Drug Metabolism Genotyping Assays, 1.75 μL
of DNAse/RNAse free water and 5 μL of diluted DNA. Initial denaturation step was 7 minutes
and 30 seconds, followed by 45 cycles of 15 at 92°C and anneal/extend for 1 min at 60°C on a
iCycler iQ™ Real-Time PCR Detection System BioRad Machine.
Determination of CBZ, CBZE and CBZD by HPLC-UV-DAD
Plasma samples for analyses were obtained from whole blood by centrifugation at 4000 rpm
for 4 minutes. Measurement of plasma CBZ, CBZE and CBZD was carried out using an Ultra
Fast Liquid Chromatographic System (Schimadzu-Japan).
Chromatographic separations were done using a reversed-phase column (KINETEX C18
5 μm, 150 x 4.6 mm i.d., Phenomenex, Castel Maggiore, Bologna, Italy), run in isocratic condi-
tions with acetonitrile/water (20:80) mobile phase at a flow rate of 1.5 ml/min. Column
temperature was 25°C. The DAD detector operated between 200 nm and 400 nm, and the
monitoring wavelengths were set at λ = 285 nm for CBZ monitoring, λ = 250nm for phenacetin
and λ = 215 nm for CBZE and CBZD. Method validation was developed following recommen-
dation for validation of bioanalytical methods of European Medicine Agency guideline.
Sample preparation was carried out using solid-phase extraction. Calibration curves were
built using blank plasma spiked with previously prepared standards for analyses from stock
solutions of CBZ, CBZE and CBZD (Sigma-Aldrich). OASIS Hydrophylic-Lipophilic-Balanced
sorbent cartridges (HLB, 30mg, Waters Corporation, Millford, MA) were used for extraction.
Cartridges were first preconditioned with 1 mL of pure methanol, followed by washing out of
the solvent with 1 mL of MilliQ water. 50 μL of IS solution (25 μg/mL phenacetin in methanol)
was added to each 250 μL sample, followed by sample vortex-mixing for 30 seconds, centrifu-
gation at 6000 G and supernatant loading on solid phase extraction cartridge. After washing
with 1 mL of 5% methanol in MilliQ water, analytes were recovered with 500 μL of absolute
methanol and 10 μL injected in the HPLC system.
Table 1. Patient characteristics and dose-adjusted concentrations and reciprocal ratios of CBZ and
its major metabolites CBZE and CBZD. CBZE: carbamazepine-10,11-epoxide; CBZD: 10,11-dihydroxy-
carbazepine.
Characteristics Patients Controls
Total patients (n) 145 100
Sex (male/female) 82/63 58/42
Age (years) 32.9±15.5 30.4±14.4
Weight (Kg) 68.3±16.0 66.5±15.5
CBZ maintenance dose (mg/Kg per day) 8.18±3.91 -
Drug resistance/response 48/97 -
CBZ plasma concentration (μg/mL) 6.78±2.78 -
CDRCBZ (μg/mL per mg/Kg) 0.56±0.55 -
CBZE plasma concentration 0.74±0.48 -
CDRCBZE (μg/mL per mg/Kg) 0.24±0.18 -
CBZD plasma concentration 1.81±1.38 -
CDRCBZD (μg/mL per mg/Kg) 0.24±0.18 -
CBZD:CBZE 2.99±2.57 -
doi:10.1371/journal.pone.0142408.t001
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Statistical analysis
All data were expressed as mean and standard deviation (SD). Before statistical analysis, nor-
mal distribution and homogeneity of the variances were tested. Associations between the
experimental parameters were investigated using one-way ANOVA, followed by t-tests on
pairwise comparisons with the least square difference (LSD) post hoc adjustment for multiple
comparisons. Apparent CBZ clearance (CL) was calculated according to the formula:
CL ¼ F CBZmaintenance dose
CBZplasma concentration  ðtÞ
where CBZplasma concentration is plasma CBZ concentration at steady state, F is bioavailability
and (τ) is the dosing interval [30,31]. Genotype frequencies were checked with Hardy—Wein-
berg equilibrium using χ2 test. The relationship between various genotypes and responsiveness
was examined using binary logistic regression. Associations were expressed as odds ratios (OR)
or risk estimates with 95% conﬁdence intervals (CI) and considered signiﬁcant when P-value
was<0.05. Statistical analysis was performed using the R-commander GUI for R (v. 3.1.3)
[32].
Results
Quantitative determination of CBZ, metabolites and related parameters
CBZ daily dose showed direct correlations with the plasma levels of both CBZ (R = 0.58,
P<0.001) and CBZE (R = 0.37, P<0.001) (S1 Fig). Plasma concentrations of the active metabo-
lite, CBZ-10,11-epoxide (CBZE), were significantly correlated to CBZ plasma levels (R = 0.58,
P<0.001; Fig 1).
Impact of sodium channel SNPs on the prevalence of epilepsy
We first studied whether two SNPs in sodium channel (SNC1A) affect the prevalence of epi-
lepsy. Genotyping these two SNPs in epileptic patients and healthy controls revealed that
carriers of the SCN1A IVS5-91G>A variant were at increased risk of epilepsy susceptibility
(P = 0.033; OR 1.80, 95% CI 1.048, 3.094), while no impact for SCN1A c.3184A>G SNP was
observed (Fig 2). Data regarding the prevalence of all the SNPs investigated in epileptic patients
compared to controls are shown in (S1 Table).
Impact of gene variants in genes influencing CBZ metabolism and
disposition parameters and CBZ metabolite plasma levels
Patients carrying the AA variant/genotype of the SCN1A IVS5-91G>A gene showed increased
maintenance dosage (Fig 3B), reduced CBZ plasma levels (Fig 3C) and increased CBZD to
CBZ ratio (Fig 3D) (Table 2), despite taking higher CBZ daily dosage compared to GA or GG
carriers (694±313 mg/day for AA compared to 509±248 mg/day for GA and 531±254 mg/day
for GG. P<0.05, Fig 3A).
Whether these differences could be the consequence of a different pharmacodynamic
response to CBZ in carriers with AA compared to GA or GG carriers, remains to be addressed.
Furthermore, no significant difference in CBZ CL values associated with any of the SNPs inves-
tigated in this study, or with patients CBZ responsiveness/resistance, was observed (results not
shown).
SCN1A c.3184A>G SNP does not affect CBZ metabolism (Table 2). The same observation
applies to ABCB1 3435C>T, where differences in daily dosage of CBZ are lost following adjust-
ment for body weight (Table 2). Similarly, plasma levels of CBZ and its metabolites were not
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Fig 1. Correlation between CBZ and CBZE plasma concentrations (Pearson’s correlation coefficient R).
doi:10.1371/journal.pone.0142408.g001
Fig 2. Graphical representation of adjusted odds ratio and 95% confidence intervals according to the
SCN1A genes polymorphism; genotype and allele frequencies in epilepsy patients vs. healthy control
subjects.
doi:10.1371/journal.pone.0142408.g002
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affected by these two SNPs (Table 2). GG carriers of the EPHX1 c.416A>G SNP showed a
reduced CBZ metabolism (mediated by CYP oxidation followed by microsomal epoxide hydro-
lase activity) compared to AA carriers as reflected by a significantly decreased ratio of CBZD to
CBZ (0.13±0.08 to 0.26±0.17; P<0.05, Fig 4A), CBZD to CBZE ratio (1.74±1.06 to 3.08±2.90,
P<0.05) (Fig 4B) and CDRCBZD (0.13±0.08 to 0.24±0.19 16 μg/mL per mg/Kg; p<0.05, Fig 4C)
(Table 2). It is worth noting that another SNP in EPHX1 (c.337T>C) affected CBZ plasma lev-
els in carriers of the rare allele, showing significant lower CDRCBZ compared to carriers of the
wild type allele (TT 0.94±0.49 μg/mL per mg/Kg, CC 0.76±0.16 μg/mL per mg/Kg; P<0.05, Fig
5) (Table 2). In summary, SNPs in EPHX1 might affect microsomal epoxide hydrolase activity
and plasma CBZ levels.
Fig 3. Graphical representations (box-plot) of the sodium channels (SCN1A IVS5-91 G>A) SNPs genotypes associations with (A) CBZ daily dosage
(mg/day), (B) CBZmaintenance dose (mg/kg per day), (C) CDRCBZ and (D) CBZD:CBZ. Statistical significance for difference of means is shown (P
values, one way ANOVA analysis followed by Student’s T-test).
doi:10.1371/journal.pone.0142408.g003
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Table 2. CBZ daily dose, maintenance dose, concentration/dose adjusted ratios of CBZ, CBZE, CBZD and their concentration ratios stratified by
individual SNPs genotypes. Data are mean ± standard deviations.
SNP n CBZ daily
dose (mg/
day)
CBZ maintenance
dose (mg/Kg per day)
CDRCBZ (μg/
mL per mg/
Kg)
CDRCBZE (μg/
mL per mg/Kg)
CDRCBZD (μg/
mL per mg/Kg)
CBZE:
CBZ
CBZD:
CBZ
CBZD:
CBZE
SCN1A IVS5-
91G>A
rs3812718
GG 50 509.3±248.0a 7.79±3.90a 1.11±0.69a 0.12±0.13a 0.23±0.15a 0.10
±0.06a
0.23
±0.13a
3.00
±2.45a
GA 79 531.6±249.2a 7.96±3.46a 0.92±0.46a 0.10±0.07a 0.23±0.19a 0.13
±0.12a
0.27
±0.22a
2.78
±2.44a
AA 16 693.8
±313.0b*
10.48±5.32b* 0.71±0.28b* 0.08±0.04a 0.28±0.10a 0.14
±0.08a
0.43
±0.17b**
4.20
±3.17a
SCN1A
c.3184A>G
rs2298771
AA 25 524.0±238.5a 7.57±3.85a 1.13±0.71a 0.11±0.11a 0.22±0.14a 0.11
±0.06a
0.22
±0.14a
2.87
±2.56a
AG 83 522.9±245.5a 8.06±3.66a 0.93±0.49a 0.10±0.08a 0.24±0.20a 0.12
±0.12a
0.26
±0.21a
2.98
±2.59a
GG 37 596.4±313.8a 8.86±4.16a 0.93±0.58a 0.11±0.13a 0.23±0.11a 0.12
±0.06a
0.29
±0.16a
3.02
±2.62a
ABCB1
3435C>T
rs1045642
CC 26 440.4±210.7a 7.78±4.51a 0.98±0.36a 0.12±0.10a 0.26±0.23a 0.11
±0.06a
0.23
±0.14a
2.55
±1.64a
CT 85 594.4
±270.0b*
8.56±3.88a 0.92±0.49a 0.10±0.06a 0.22±0.14a 0.12
±0.10a
0.26
±0.17a
2.98
±2.57a
TT 34 525.4±253.3a 8.05±3.59a 1.00±0.66a 0.11±0.13a 0.21±0.15a 0.11
±0.06a
0.24
±0.16a
3.36
±3.18a
EPHX1
c.416A>G
rs2234922
AA 80 542.8±251.4a 8.11±3.49a 1.00±0.62a 0.12±0.12a 0.24±0.19a* 0.12
±0.09a
0.26
±0.17a*
3.08
±2.90a
AG 55 540.0±276.0a 8.16±4.27a 0.94±0.53a 0.09±0.05a 0.21±0.14b 0.11
±0.08a
0.24
±0.17b
3.95
±2.44a
GG 10 510.0±202.5a 8.37±2.69a 1.05±0.29a 0.09±0.05a 0.13±0.08b 0.10
±0.06a
0.13
±0.08b
1.74
±1.06b*
EPHX1
c.337T>C
rs1051740
TT 63 523.2±257.3a 8.25±4.07a 0.94±0.49a 0.12±0.12a 0.26±0.16a 0.13
±0.12a
0.31
±0.22a*
3.29
±2.69a
TC 72 553.6±279.4a 8.07±3.96a 1.02±0.64a 0.10±0.07a 0.22±0.18a 0.11
±0.09a
0.23
±0.16b
2.86
±2.74a
CC 10 620.0±147.6a 9.26±2.85a 0.76±0.15b* 0.07±0.05a 0.18±0.17a 0.10
±0.07a
0.25
±0.17b
3.20
±3.06a
a,b Values sharing same letter are not signiﬁcantly different.
*P<0.05
**P<0.01. (one way ANOVA analysis followed by Student’s T-test). CBZE: carbamazepine-10,11-epoxide; CBZD: 10,11-dihydroxy-carbazepine.
doi:10.1371/journal.pone.0142408.t002
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In addition, according to the report by Puranik et al. for a Caucasian population [17], haplo-
type analysis of EPHX1 gene was carried out and no significant association was found with the
above parameters (S2 Fig).
Assessment of CBZ resistance
Finally, we assessed whether the plasma levels of CBZ and its metabolites represent markers
of responsiveness to CBZ treatment. While increased CBZ daily and maintenance doses in
Fig 4. Graphical representations (box-plot) of the EPHX1 c.416A>G genotypes associations with (A) CBZD:CBZ, (B) CBZD:CBZE and (C)
CDRCBZD,. CBZ: Carbamazepine; CBZD: Carbamazepine-10,11-trans dihydrodiol; CBZE: Carbamazepine-10,11-epoxide; CDR: Concentration/dose ratio.
Data are mean ± standard deviations. Statistical significance for difference of means is shown (P values, one way ANOVA analysis followed by Student’s T-
test).
doi:10.1371/journal.pone.0142408.g004
Fig 5. Graphical representations (box-plot) of the EPHX1 c.377T>C genotypes with CDRCBZ CBZ:
Carbamazepine; CDR: Concentration/dose ratio. Data are mean ± standard deviations. Statistical
significance for difference of means is shown (P values, one way ANOVA analysis followed by Student’s T-
test).
doi:10.1371/journal.pone.0142408.g005
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resistant patients compared to responsive patients (657±285 vs 489±231 mg/day; P<0.001)
(Fig 6A and 6B) are expected, the observation that resistant patients also presented increased
CBZ plasma levels (9.84±4.37 vs 7.41±3.43 μg/mL; P<0.001) (Fig 6C) is surprising.
To verify whether the differences in CBZ plasma levels were only due to the increased daily
CBZ dose or maintenance dose, resistant and responsive patients were matched according to
the dose of CBZ administered, by excluding n = 43 patients taking the lowest CBZ doses from
the responsive group. The results of this analysis showed that CBZ plasma levels were still
increased in resistant patients compared to responsive patients (S2 Table).
Indeed, none of the SNPs investigated here resulted in association with CBZ drug respon-
siveness in epilepsy patients (Table 3).
Discussion
The present study investigated the effects of polymorphism of genes encoding the major drug
transport, metabolizing enzymes and target proteins, on plasma concentrations of CBZ and its
related metabolites (CBZE and CBZD). This was conducted in order to detect the interindivid-
ual variability in Kosovar patients of Albanian ethnicity with respect to CBZ pharmacodynam-
ics, as well as its metabolism and disposition in patients with epilepsy.
Our results show that the mean concentrations of CBZ, CBZE and CBZD and their ratios in
our cohort were comparable to those previously reported for other Oriental and Caucasian
populations [17–19,21,28]. In addition, the correlation coefficients observed between daily
dose and plasma CBZ and CBZE were in agreement with those reported by Krasniqi et al. for a
German population of epileptic patients [33].
Our study has three key findings: (i) the SCN1A IVS5-91G>A SNP is associated with sus-
ceptibility to epilepsy, (ii) SNPs in EPHX1 gene influence CBZ pharmacokinetic and (iii) CBZ
plasma level is not an indicator of resistance to the therapy.
The sodium channel α-subunit is the major binding site of several antiepileptic drugs.
Therefore, the interest in genes encoding for this protein lies not only in the possible causal
roles in epilepsy, but also in the potential effects on the antiepileptic drug efficacy.
There are several isoforms of α -subunits expressed in the brain, which are encoded by
SCN1A, 2A, 3A and 8A [34,35]. Differential influence of genetic variants, namely SCN1A
c.3184A>G and SCN1A IVS5-91, in epilepsy susceptibility and drug response have previously
Fig 6. Graphical representations (box-plot) of the assessment of CBZ resistance due to patient response to therapy (A) CBZ daily dosage (mg/
day), (B) CBZmaintenance dose (mg/kg per day) and (C) CBZ plasma concentration (μg/mL).Data are mean ± standard deviations. Statistical
significance for difference of means is shown (P values, Student’s T-test).
doi:10.1371/journal.pone.0142408.g006
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been reported [36–38]. These two SNPs were selected since, by belonging to a linkage disequi-
librium block, they can be representative of other SNPs in the SCN1A gene [15,39].
Our results, which show increased mean CBZ maintenance dose, lower CDRCBZ and higher
CBZD:CBZ ratio in carriers of the IVS5-91G>AG variant of the SCN1A channel, are in agree-
ment with previous findings in Caucasian patients [40,41]. Similar results were reported by
Hung and colleagues, which showed in a Taiwanese population that carriers of the variant
SCN1A IVS5–91G>A required higher CBZ dosages and lower ln(concentration–dose ratios)
compared to noncarriers [15]. Recently, these patterns have been confirmed by Ma and col-
leagues in a population of Chinese patients [42]. Furthermore, increased doses of CBZ are asso-
ciated with increased mean steady-state concentrations of CBZD [43], which could be linked to
the effect of the SCN1A gene, IVS5–91 G>A variant, on CBZ dosage and CBZD:CBZ ratio.
Not all papers are in agreement with the findings above [44,45]. Whether ethnicity plays a
role, remains to be addressed.
In addition, we also observed genetic variations in the genes encoding the expression of
cerebral sodium channels in the epilepsy phenotypes compared to healthy control subjects,
suggesting the involvement of this genotype in increased risk for developing epilepsy. These
findings warrant further confirmation in future studies involving larger cohorts.
Previously, the impact of variants on a drug efflux transporter protein involved in the efflux
of antiepileptic drugs, namely P-glycoprotein (Pgp; encoded by ABCB1 or MDR1), has been
studied in different ethnic groups [46,47]. However, conflicting results have been reported,
Table 3. Distribution of SCN1A, ABCB1, EPHX1 genes polymorphism in drug-resistant and drug-responsive epileptic patients.
SNPs Gene/alleles CBZ Resistance(n = 46) CBZ Responsive (n = 99) Odds Ratio (95% Cl) P-Value
SCN1A IVS5-91G>A GG 16 (34.8%) 34 (34.3%) reference
rs3812718 GA 25 (54.3%) 54 (54.6%) 0.98 (0.460, 2.104) 0.97
AA 5 (10.9%) 11 (11.1%) 0.97 (0.287, 3.248) 0.96
GG 16 (34.8%) 34 (34.3%) reference
GA+AA 30 (65.2%) 65 (65.7%) 0.98 (0.470, 2.045) 0.97
SCN1A c.3184A>G AA 8 (17.4%) 17 (17.2%) reference
rs2298771 AG 27 (58.7%) 56 (56.5%) 1.02 (0.393, 2.669) 0.96
GG 11 (23.9%) 26 (26.3%) 0.90(0.300, 2.693) 0.85
AA 8 (17.4%) 17 (17.2%) reference
AG+GG 38 (82.6%) 82 (82.8%) 0.99 (0.391, 2.481) 0.97
ABCB1 3435C>T CC 8 (17.4%) 18 (18.2%) reference
rs1045642 CT 28 (60.9%) 57 (57.6%) 1.11 (0.428, 2.851) 0.84
TT 10 (21.7%) 24 (24.2%) 1.06(0.421, 2.643) 0.91
CC 8 (17.4%) 18 (18.2%) reference
CT+TT 38 (82.6%) 81 (81.8%) 1.06(0.421, 2.643) 0.91
EPHX1 c.416A>G AA 25 (54.4%) 55 (55.6%) reference
rs2234922 AG 18 (39.1%) 37 (37.3%) 1.07(0.513, 2.233) 0.86
GG 3 (6.5%) 7 (7.1%) 0.94(0.225, 3.950) 0.94
AA 25 (54.4%) 55 (55.6%) reference
AG+GG 21 (45.6%) 42 (43.8%) 1.05 (0.543,2.228) 0.79
EPHX1 c.337T>C TT 23 (50%) 40 (40.4%) reference
rs1051740 TC 21 (45.6%) 51 (51.5%) 0.72 (0.348,1.474) 0.36
CC 2 (4.4%) 8 (8.1%) 0.44(0.085,2.224) 0.31
TT 23 (50%) 40 (40.4%) reference
TC+CC 23(50%). 59 (59.6%) 0.68 (0.335, 1.370) 0.28
doi:10.1371/journal.pone.0142408.t003
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with some works indicating an impact on antiepileptic drug resistance [48–51], while others
are in agreement with our observation, showing no effect of ABCB1 3435C>T on CBZ phar-
macokinetic and drug response [52–55].
CYP3A4/A5 enzymes play a major role in the CBZ metabolism and in the onset of epilepsy
pharmacoresistance [56–58]. Subsequent analyses aimed at addressing the contribution of
CYP3A4 protein variants to the inter-individual variability of CYP3A4 activity were, however,
less clear [59] or even observed a lack of effect of CYP3A4/5 variants on CBZ metabolism in
both European Caucasian or in Asian populations [17,21,60,61].
For this reason, we decided to focus the investigation on the impact of SNPs in other genes
that could explain CBZ pharmacoresistance beyond those in CYP3A4/A5 enzymes, including
mEH, which has been proposed as a predictor of maintenance dose [27]
The human mEH, encoded by the EPHX1 gene, is expressed polymorphically [62]. The
presence of two common variants, c.337T>C and c.416A>G, has been suggested to influence
the catalytic activity of mEH in vitro and in vivo [63,64]. Further studies have shown that enzy-
matic expression levels and activity are altered and a significant association of EPHX1 SNPs
with increased or decreased CBZD:CBZE ratios was found [15, 65–68], although this was not
consistent in all studies [21]. While CBZD:CBZ is an indicator of enzymatic conversion of
CBZ, dependent on both CYP enzymes and/or mEH, useful in determining unexpected CBZ
levels [69], CBZD:CBZE ratio is considered as a sensitive indicator of mEH activity [15, 65–
68]. This ratio was significantly lower in carriers of the variant EPHX1 c.416A>G, suggesting a
reduced activity of the mEH, while the similarity of CBZE:CBZ ratio in carriers versus non car-
riers limits the relevance of differences in CYP enzyme activity.
We show here that variants in EPHX1 affect CBZ metabolism, either resulting in no effect
on CDRCBZ or reduced CBZD:CBZ, CBZD:CBZE ratios and CDRCZBD, which is in agreement
with reports by Nakajima et al. [67] in the case of c.416A>G. We also observed that another
EPHX1 variant (c.337T>C) is associated with lower CDRCBZ, in agreement with associations
found by other authors [15,27]. However, as it is known that CBZ is not a direct substrate of
mEH, the possibility of using CBZ plasma levels as a surrogate indicator for the evaluation of
mEH activity has to be considered.
Previous studies have shown that SCN1A splice variants (encoding Nav I.I channels) play a
role in epilepsy susceptibility, with recent evidence of drug sensitivity due to tonic and use-
dependent block of Nav1.1-5A and Nav1.1-5N, with therapeutically CBZ concentrations, show-
ing more preferential activity for other reported AEDs than CBZ. [70,71]
Finally, we observed that resistant patients presented significantly increased daily dose,
maintenance dose and plasma levels of CBZ. To exclude that the latter could simply be the con-
sequence of increased administered dose, we compared responsive and resistant patients
matched for the daily dose and still observed significantly increased plasma CBZ levels. Previ-
ous studies showed that in resistant patients access of CBZ to the brain was limited by the
blood-brain barrier [72–74]. Whether this could, at least in part, explain our findings remains
to be explored.
In conclusion, by showing a critical effect of polymorphisms in the response and efficacy of
CBZ treatment in epileptic patients with a main focus on CBZ and metabolites, our work may
set the stage for larger investigational studies aimed at evaluating the impact of pharmacogeno-
mic approaches in the clinical management of patients with epilepsy.
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